Samsung to invest 300 billion won in biosimilars business

Published: 2011-03-02 06:59:00
Updated: 2011-03-02 06:59:00
Samsung Group said Friday it plans to set up a biopharmaceutical joint venture with Quintiles Transnational Corp., a U.S. drugmaker based in North Carolina.

The company said the joint venture will be established during the first half of this year, to be capitalized at 300 billion won ($265.5 m...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.